BridgeBio Unveils New Solid Tumor Anticancer Candidate 'BBT-4437'

Innovative new drug research and development company Bridge Biotherapeutics announced on the 22nd that it has confirmed poster presentations for one clinical project and one non-clinical project at the international cancer research conference ‘2023 AACR-NCI-EORTC.’

Bridge Biotherapeutics logo
[Photo by Bridge Biotherapeutics]

The AACR-NCI-EORTC, held over five days from October 11 to 15 in Boston, USA, is an academic conference jointly hosted by the American Association for Cancer Research (AACR), the U.S. National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC). It is expected to bring together global academic and industry stakeholders from the U.S., Europe, and beyond to engage in diverse discussions on anticancer treatments and new drug development.

The company plans to present key preclinical data and an overview of clinical trials for its lung cancer treatment candidate ‘BBT-207,’ which entered the clinical phase after receiving Investigational New Drug (IND) approvals from the U.S. Food and Drug Administration (FDA) in April and the Korean Ministry of Food and Drug Safety this month, in poster format. At the 2023 AACR Annual Meeting held in April, the company also disclosed BBT-207’s antitumor efficacy and brain metastasis inhibition based on preclinical data through a poster presentation. This time, the Phase 1 and 2 clinical trial overview and plans for BBT-207, developed as a fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), will be revealed. Meetings with global lung cancer clinical researchers gathered locally are also expected to be held to facilitate the prompt initiation and progress of the clinical trials.

Bridge Biotherapeutics will also unveil for the first time its newly discovered solid tumor treatment candidate ‘BBT-4437’ through its Boston-based subsidiary, Boston Discovery Center (BDC). BBT-4437 is a novel TEA domain (TEAD) targeted inhibitor with anticancer efficacy by inhibiting the Hippo signaling pathway. The Hippo signaling pathway is known to regulate the number of cells within tissues in the body to maintain normal ranges. When mutations occur in the pathway’s constituent proteins, regulatory molecules called YAP/TAZ bind to specific DNA regions and interact with TEAD, a key transcription factor protein that promotes or suppresses gene expression, leading to various diseases including cancer. BBT-4437 is expected to exhibit excellent selectivity in inhibiting TEAD protein binding activity as well as superior brain penetration.

The company plans to disclose various early experimental data on BBT-4437 through this poster presentation. Subsequently, it will establish development strategies considering various solid tumors, including malignant mesothelioma and tumors containing NF2 mutations.

Lee Jung-kyu, CEO of Bridge Biotherapeutics, stated, “Following BBT-176, BBT-207, which can respond to a wider range of mutations, has now entered the clinical phase. We plan to continuously present meaningful achievements by newly unveiling TEAD-targeted inhibitors, which have recently emerged as attractive targets in the global anticancer drug field.”

This content was produced with the assistance of AI translation services.